SPARC receives Priority Review Voucher associated with Sezaby approval
Sun Pharma Advanced Research Company (SPARC) announced that the United States Food and Drug Administration (FDA) has granted a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sun Pharma Advanced Research Company
SPARC wins U.S. court ruling on Sezaby Priority Review Voucher
U.S. District Court grants summary judgment in SPARC’s favour on Sezaby-linked voucher
Sun Pharma ends development of SCD-044 after phase 2 trials fail to meet primary endpoints
SCD-044 trials for psoriasis and atopic dermatitis show no major safety concerns
SPARC announces submission of IND application for SBO-154 to USFDA
SBO-154 set to enter global Phase 1 clinical trial for treatment of advanced solid tumours
PROSEEK study shows no treatment benefit of Vodobatinib in patients with early Parkinson’s Disease
Both low dose and high dose Vodobatinib arms did not meet the pre-specified primary endpoint of change in MDS-UPDRS Part III total…
SPARC completes enrolment in PROSEEK, Phase 2 study of Vodobatinib in early Parkinson’s disease
506 patients completed enrolment across 84 sites in the US, Europe and India
Sun Pharma and SPARC enter into licence agreement for commercialisation of phenobarbital for…
Product awaiting the US FDA approval, targetted at treating seizures in neonatal patients
USFDA denies application from SPARC for cancer drug
The Office of New Drugs of the US FDA requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support…
SPARC signs license agreement with Tripoint Therapeutics for Elepsia XR tablets
SPARC will be eligible to receive tiered royalties ranging from 15 per cent to 50 per cent on net sales
SPARC and Sun Pharma enter into license agreement for SCD-044
It is a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders